RESULTS	Two randomized , placebo-controlled , double-blind , crossover studies were performed for 1 month on patients with New York Heart Association Class II-III chronic heart failure , comparing 300 mg allopurinol , 600 mg allopurinol , and placebo for the first study and 1000 mg probenecid versus placebo in the second study .\